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Abstract: 
Patients presenting with acute coronary syndrome (ACS) are frequently comorbid. However, 
there is limited data on how comorbidity burden impacts their receipt of invasive management 
and subsequent outcomes. We analyzed all patients with a discharge diagnosis of ACS from the 
National Inpatient Sample (2004-2014), stratified by Charlson Comorbidity Index (CCI) into 4 
classes (CCI 0, 1, 2 and ≥3). Regression analyses were performed to examine associations 
between comorbidity burden and receipt of invasive intervention and in-hospital clinical 
outcomes. Of all 6,613,623 ACS patients analyzed, the prevalence of patients with severe 
comorbidity (CCI≥3) increased from 10.8% (2004) to 18.1% (2014). CCI class negatively 
correlated with receipt of invasive management, with CCI≥3 group being the least likely to 
receive coronary angiography and PCI (odds ratio (OR): 0.42 95%CI 0.41-0.43 and OR 0.47, 
95%CI 0.46-0.48, respectively). CCI class was independently associated with an increased risk 
of mortality and complications, especially CCI≥3 that was associated with significantly 
increased odds of MACCE (OR 1.70, 95%CI 1.66-1.75), mortality (OR 1.74, 95%CI 1.68-1.79), 
acute ischemic stroke (OR 2.35, 95%CI 2.23-2.46) and major bleeding (OR 1.64, 95%CI 1.59-
1.69). Comorbidity burden has significantly increased amongst those presenting with ACS over 
an 11-year period and correlates with reduced likelihood of receipt of invasive management and 
increased odds of mortality and adverse outcomes. In conclusion, objective assessment of 
comorbidities using CCI score identifies high-risk ACS patients in whom targeted risk reduction 
strategies may reduce their inherent risk of mortality and complications.  
 





 Cardiovascular disease remains the leading cause of death in the United States (US).1 A 
significant proportion of patients with CAD have concurrent comorbid conditions.2,3 While at 
an individual level, a patient’s comorbidities affects treatment strategy, rehabilitation potential 
and prognosis; at a population level comorbid burden has a bearing on the utilization of 
healthcare resources.4 Comorbidities rarely occur in isolation and should be considered in 
totality, considering both cardiovascular and non-cardiovascular conditions.5,6 The Charlson 
Co-morbidity Index (CCI) is a measure of co-morbidity burden and provides a means of 
quantifying the prognostic impact of 22 comorbid conditions on the basis of their number and 
individual impact by means of a score that was developed as a prognostic indicator for patients 
with a variety of medical conditions and has been shown to predict mortality, morbidity, risk of 
repeat hospitalizations, length of stay and cost of treatment. 3,7,8 Previous studies evaluating the 
impact of CCI on outcomes in acute coronary syndrome (ACS) have generally been limited to 
single center studies 9, small sample sizes 10, specific cohorts of patients, such as first time 
hospitalization for acute myocardial infarction) 11, ST-segment elevation myocardial infarction 
(STEMI) 12, or focused only on incidence of ACS and not outcomes. 13 Furthermore, there is 
limited data on temporal trends and incidence of cardiovascular and non-cardiovascular 
comorbidities from a national perspective and their influence on the management and outcomes 
of ACS patients.  As such, the present study examined temporal trends in comorbidity burden, 
as measured by CCI score, amongst patients with ACS, and evaluated its impact on utilization 




The data is extracted from the National Inpatient Sample (NIS)—the largest publicly 
available all-payer inpatient healthcare database in the United States. Further information on 
NIS dataset is available in Supplementary Appendix A.  
The study period was from January 2004 to December 2014. All adults (≥18 years) with 
the principal diagnosis of ACS were eligible for inclusion and identified by International 
Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), diagnosis codes 
410.xx (acute myocardial infarction) and 411.1 (Unstable Angina). Missing data were assumed 
to be missing at random: observations with missing data were removed if there were less than 
10% data missing in that covariate (Supplementary Figure 1). Baseline patient characteristics 
for each discharge includes age, gender, race, admission day (weekday or weekend), primary 
expected payer, median household income for patient’s ZIP code, 17 comorbidities using Deyo 
modification of the Charlson comorbidity index 14 and other clinically relevant comorbidities 
(smoking, carotid disease, atrial fibrillation, long-term use of anticoagulants, prior percutaneous 
coronary intervention (PCI), and prior coronary artery bypass grafting (CABG)).  
NIS database includes up to 30 diagnosis and 15 procedure codes, which were used to 
identify the specific conditions and each Charlson comorbidity. The components of Charlson 
comorbidity index are shown in Supplementary Table 1. A list of ICD-9-CM codes used to 
extract those diseases is provided in Supplementary Table 1a and Supplementary Table 1b. 
CCI score was calculated by summing individual scores and was analysed as a categorical 
variable and a continuous variable separately. CCI score was stratified according to severity of 
comorbidity burden into 4 groups: “0” (no comorbidity), “1” (mild comorbid burden), “2” 
(moderate comorbid burden), “≥3” (severe comorbid burden).  
The primary outcomes of interest were in-hospital MACCE (Major Acute 
Cardiovascular & Cerebrovascular Events) and major bleeding. Secondary outcomes included 
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the receipt of invasive management (PCI or coronary angiography (CA)), length of stay and 
total hospitalization charges. In-hospital MACCE was defined as a composite of mortality, 
cardiac complications, acute ischemic stroke, and vascular complications (vascular injury). 
Cardiac complications were defined as any event of pericardial effusion, cardiac tamponade, 
coronary dissection or need for pericardiocentesis) Major bleeding included any gastrointestinal, 
intracranial, retroperitoneal and procedure-related hemorrhages.  
Statistical analyses were performed using STATA version 14.0. Odds ratios (OR) and 
their corresponding 95% confidence intervals (CI) were used to report the results of models.  
Multiple imputation with chained equations (MICE) 15 was used to manage the missing data 
where missing data was more than 10% of the covariate. 10 complete datasets were generated 
with any missing covariate date imputed. All outcomes and other covariates including age, 
gender, median ZIP income and year of hospitalization were included in the imputation model 
to ensure congeniality with the analysis model 16. Further information on statistical methods is 
available in Supplementary Appendix B. 
A sensitivity analysis was performed using CCI score as a continuous variable to assess 
the impact of per unit score of CCI on in-hospital outcomes (MACCE, mortality, acute stroke 
and major bleeding). The multivariable logistic regression models for each of the 4 outcomes 
were then performed separately for the STEMI subgroup. 
Results 
A total of 6,613,623 weighted hospitalizations for ACS were included in the analysis, 
with approximately 8.5% (n=123,344) of the raw dataset excluded (Supplementary Figure 1) 
due to missing data. The median age of ACS patients was 67 (56-79) years old and changed 
little over the study period while the proportion of women decreased during the 10 years from 
41.8% to 38.5% (2004-2014) (Table 1).  The percentage of patients with STEMI decreased 
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from 39% in 2004 to 28% in 2014. Amongst the Charlson comorbidities, the prevalence of both 
cardiovascular risk factors (previous MI, peripheral vascular disease (PVD), previous 
cerebrovascular disease (CVA), and diabetes) and non-cardiovascular comorbidities such as 
metastatic disease, liver disease and chronic pulmonary disease increased over the study years. 
(Table 1). Table 2 demonstrates patient demographics stratified by CCI across all years. 
Patients with a higher comorbid burden (CCI≥2) were older compared to those with lower 
burden or no burden. Female patients were less prevalent than male patients in all the groups 
studied, however, females were more common in the severe comorbid burden cohort (45.7% in 
CCI≥3 vs. 33.9% in CCI=0). The percentage of patients without any comorbidities (CCI=0) 
declined from 37.3% in 2004 to 30.2% in 2014, whilst the percentage of patients with severe 
comorbid burden (CCI≥3) increased from 10.8% to 18.1%. (Figure 1).  
The rates of PCI and coronary angiography (CA) increased over years (32.9% in 2004 
to 46.7% in 2014; 53.3% in 2004 to 69.3% in 2014, respectively) (Figure 2) although rates of 
utilization of CABG remained stable. (Table 1) Comorbidity burden negatively correlated with 
the rate of utilization of PCI and CA (PCI: 53.5% in CCI=0 to 24.0% in CCI≥3; CA: 72.0% in 
CCI=0 to 47.0% in CCI≥3). (Table 2) In comparison to patients with no comorbidities (CCI=0), 
patients in CCI=2 were 45% less likely in the odds of receiving a PCI whereas those with CCI≥3 
were 53% less likely (OR 0.55, 95%CI 0.54-0.56 in CCI=2 and OR 0.47, 95%CI 0.46-0.48 in 
CCI≥3). A similar pattern was found in the receipt of CA. (Table 3) 
The rates of MACCE, mortality and major bleeding decreased over the included years 
(2004-2014), while the prevalence of cardiac complications increased negligibly over time. The 
rates of acute ischemic stroke and vascular complications did not change. (Table 4) The rates 
for MACCE, mortality, acute ischemic stroke and major bleeding increased with increasing 
comorbid burden (MACCE: 5.4% in CCI=0 to 11.4% in CCI≥3; mortality: 3.3% in CCI=0 to 
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8.1% in CCI≥3; acute ischemic stroke: 0.9% in CCI=0 to 3.0% in CCI≥3; major bleeding: 3.9% 
in CCI=0 to 6.1% in CCI≥3). (Figure 3, Table 5) 
 The results of multivariable regression demonstrated increased comorbid burden was 
independently associated with increased odds of MACCE and mortality (Table 3). For example, 
compared with the reference category (CCI=0), CCI≥3 was significantly associated with a 70% 
increase in the odds of MACCE and 74% increase mortality (OR 1.70, 95%CI 1.66-1.75 and 
OR 1.74, 95%CI 1.68-1.79).  CCI=2 was associated with a 35% increase in the odds of MACCE 
(OR 1.35, 95%CI 1.32-1.38) and an almost 50% increase in the odds of mortality (OR 1.45, 95% 
1.41-1.50). Patients with CCI scores of 1, 2, ≥3 had increased odds of acute ischemic stroke 
and major bleeding compared to those patients with CCI=0, with CCI≥3 having about 2.5-fold 
in the odds of acute ischemic stroke (OR 2.35, 95%CI 2.23-2.46). The results of the sensitivity 
analysis by keeping CCI as a continuous variable are presented in Supplementary Table 2 with 
similar findings to the main analysis. Each unit increase in CCI score was associated with 
increased odds of all outcomes (MACCE, mortality, acute ischemic stroke and major bleeding).  
In a subgroup analysis of STEMI patients, similar findings were reported to the main 
analysis. (Supplementary Table 3) The prognostic impact of each individual Charlson 
comorbidity using multivariable models on clinical outcomes was presented in Supplementary 
Table 4. 
Patients with a CCI score 0 and 1 had a similar median length of stay (3 days), which 
was up to 4 days for CCI=2 and 5 days for CCI≥3. (Table 2) A similar trend was also found in 
the association of hospital costs with increasing comorbid burden: median cost of 




 We present the largest study to date analyzing the temporal trends in comorbidity burden 
(characterized by the CCI) and their impact on prognosis and treatment in patients with ACS. 
We report that the prevalence of severe comorbidity burden as defined by CCI doubled from 
one in ten patients to almost one in five over a period of eleven years (2004-2014). This was in 
the absence of any obvious change in the age distribution of admitted ACS patients and a slight 
reduction in the proportion of ACS patients who were female. We observed that ACS patients 
with severe comorbid burden (CCI≥3) are least likely to receive coronary angiography or PCI, 
and that increasing comorbidity burden was independently associated with an increased risk of 
MACCE, acute ischemic stroke, major bleeding complications and mortality. Finally, 
increasing comorbidity was associated with an increased  hospitalization cost and length of stay. 
 Our analysis reveals that patients presenting with ACS are increasingly comorbid and 
complex with a multitude of cardiovascular and non-cardiovascular comorbidities. Previous 
studies have shown that among patients with acute MI, the prevalence of cardiovascular risk 
factors and comorbidities such as diabetes, hypertension, heart failure and atrial fibrillation 
increased during 1990 to 2007. 2,17 However these studies were either smaller in sample size 
2,17 or community based study restricted to a particular geographic area 2. When patient 
demographics were stratified by CCI score we found that ACS patients with severe comorbid 
burden were older and with greater percentage of women.  
 In this study we report that in-hospital mortality significantly increases with increasing 
comorbid burden. When patients with no comorbidities (CCI=0) were compared to patients 
with CCI=1, 2 and ≥3 comorbidities, the risk of mortality increased by 31%, 45% and 74% 
respectively. Previously our large meta-analysis 3 of studies 9-13,18-21 evaluating the impact of 
CCI score on cardiovascular diseases demonstrated that among ACS patients the risk of 
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mortality was significantly higher with an incremental increase in CCI score. Three studies 
10,13,21 demonstrated that patients with any comorbidities (CCI>0) had nearly two times the risk 
of death (RR 1.93; 95%CI 1.67–2.24) compared to those with CCI=0 3. Whilst in our study only 
in-hospital mortality was evaluated, multiple other studies have shown CCI score to be a 
predictor of mortality even at 1 year. 10,11,20  
 In our analysis the most notable of in-hospital complications that increased significantly with 
increase in CCI was the occurrence of acute ischemic stroke and major bleeding. The risk of 
acute ischemic stroke in CCI≥3 was almost 2.5-fold that in CCI=0. Additionally, post-PCI 
stroke was associated with a significantly higher mortality and increased length of stay. Our 
analysis also revealed that there was an increasing risk of occurrence of major bleeding 
complications with increase in CCI score. An expert consensus document on high bleeding risk 
recognizes several of the components of CCI such as advanced age, chronic kidney disease, 
liver disease, history of stroke or gastrointestinal bleed, as independent risk factors for bleeding 
following PCI 22, although does not consider measures of overall comorbid burden. 23  
 Previous analyses have not been powered to study the prognostic impact of individual 
comorbid conditions that make up CCI. Our analysis suggests that the individual components 
of CCI with greatest prognostic impact are mainly non-cardiovascular comorbid conditions that 
are not routinely included in ACS prognoses scores such as cancer, moderate or severe liver 
diseases, peptic ulcer diseases and neurological deficits such as hemiplegia or paraplegia.  
 The adverse outcomes that we report to be associated with increasing CCI are likely to be 
multifactorial, with patients with severe comorbid burden at increased risk of both recurrent 
ischemic events and mortality. Paradoxically, a notable finding of our study is that ACS patients 
with severe comorbid burden are more likely to be conservatively managed as compared to 
their counterparts with lesser or no comorbidities. Previously the AMI Florence working group 
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reported that coronary reperfusion strategy was less frequently adopted in patients with 
increasing chronic comorbidity score based on data analysis of a population-based registry with 
a smaller sample size (N=740), which included only STEMI patients. 24 The same group also 
demonstrated that application of PCI was associated with a long-term survival advantage that 
increased progressively with increase in risk profile in ACS patients and hypothesized that a 
conservative approach in these multimorbid patients may not justified. 25 In a further study, 
Nunez et al. demonstrated that a higher CCI score was an independent predictor of 30 day and 
1 year of the composite mortality or acute myocardial infarction endpoint. 9 Such patients at 
higher risk of ischemic complications are more likely to benefit from an early invasive approach, 
but this must be balanced against the increased risk of complications such as major bleeding, 
stroke and cardiovascular complications. 23 A previous study of 1202 ACS patients has shown 
that addition of CCI to the GRACE score improved the prediction of future cardiovascular 
events and mortality 18, whilst CCI has been shown to be one of the strongest predictors of non-
CV mortality in patients undergoing PCI 26. Incorporation of CCI into risk stratification tools 
may help guide the management of this complex group of patients. An analysis of the National 
Readmissions Database revealed that CCI≥3 was the foremost predictor of 30-day readmission 
among patients with non-ST elevation ACS. 27 
 Finally, we also report that comorbidity burden may have an important health economic 
impact in patients with ACS, we observe an incremental increase in the median adjusted cost 
of hospitalization of ACS patients with increase in comorbidity burden ($17675 in CCI=0 to 
$21139 in CCI≥3). As expected, the median length of stay also increased with increasing 
comorbidity burden (5 days for CCI≥3 group as compared to 3 days for CCI=0). In general 
although length of stay for STEMI patients have been shown to have decreased over time 28, 
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those that do have a longer length of stay have been associated with higher morbidity and 
mortality 29,30.  
 Unlike our current study, previous studies have failed to comprehensively evaluate the 
impact of CCI on management strategy and occurrence of complications such as bleeding, 
stroke, vascular and cardiac complications. We acknowledge several limitations of our study, 
which are inherent to the NIS database. Like with any other administrative database, coding 
errors and underreporting of secondary diagnoses are a potential source of bias. The NIS 
database also does not capture the exact cause of death and lacks data regarding long term 
outcomes thereby limiting us to just in-hospital events. Additionally, the NIS database lacks 
formal adjudication of outcomes, and events such as bleeding are not defined based on 
standardized definitions used in cardiovascular trials. 31 
In conclusion, our temporal analysis of ACS hospitalizations suggests that comorbidity 
burden has significantly increased amongst in this population over an 11-year period, and 
correlates with reduced likelihood of receipt of invasive management and increased odds of 
mortality and adverse outcomes. Objective assessment of comorbidities using CCI score 
identifies high-risk ACS patients in whom targeted risk reduction strategies may reduce their 
inherent risk of mortality and complications. 
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Figure Titles and Legends:  
 
Figure 1. Distribution of the CCI groups across the study years (2004-2014). 
Legend: CCI: Charlson comorbidity index. 
 
Figure 2: Rates of PCI and CA according to CCI groups between 2004 and 2014. 
Legend: PCI: percutaneous coronary intervention; CA: coronary angiography; CCI: Charlson 
comorbidity index. 
 
Figure 3: Rates of MACCE, mortality, acute ischemic stroke and major bleeding 
according to CCI groups between 2004 and 2014. 
Legend: MACCE: Major Acute Cardiovascular & Cerebrovascular Events; CCI: Charlson 
comorbidity index. 
 
Table 1. Secular trends of baseline characteristics between 2004 and 2014 in ACS patients. 
Variable 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Missing 
Patients demographics  
No. of unweighted 
discharges with ACS 
diagnosis 
157,239 146,475 149,034 135,694 139,142 133,265 127,600 133,505 126,622 124,853 125,833 None 
No. of weighted 
discharges with ACS 
diagnosis 
647,068 611,467 677,163 612,637 594,553 585,658 547,855 549,441 602,020 594,590 589,860 None 
No. of weighted 


















































Female, % 41.8% 41.5% 40.6% 41.0% 40.9% 40.1% 40.0% 39.8% 38.4% 38.8% 38.5% 
1035 
(0.014%) 
Race, %  
White 55.9% 57.3% 57.0% 55.9% 61.7% 63.3% 65.6% 66.9% 71.0% 70.7% 71.0% 
1,255,683 
(17.4%) 
black 7.0% 5.5% 6.7% 7.5% 7.4% 7.8% 9.9% 9.7% 10.1% 10.1% 10.2% 
Hispanic 5.2% 5.5% 5.8% 5.6% 5.3% 6.1% 6.4% 7.4% 7.2% 7.6% 7.4% 
Asian/Pacific islander 1.5% 1.2% 1.4% 1.8% 1.9% 1.8% 2.0% 2.0% 2.1% 2.3% 2.3% 
Native American 0.2% 0.2% 0.4% 0.5% 0.7% 0.5% 0.4% 0.6% 0.5% 0.5% 0.5% 
other 2.0% 2.3% 2.0% 2.3% 2.9% 3.6% 2.4% 2.9% 3.2% 2.8% 3.0% 
Missing Race 28.1% 27.9% 26.7% 26.4% 20.1% 16.9% 12.8% 10.6% 5.9% 6.1% 5.5% 
Admission/weekend, % 25.0% 25.1% 24.9% 25.5% 26.3% 25.9% 26.4% 26.2% 25.9% 26.5% 26.3% None 
Median zip code income national quartile, %  
Frist 28.3% 28.4% 27.1% 28.6% 28.3% 29.0% 29.3% 29.2% 31.5% 30.0% 29.6% 
172846 
(2.4%) 
Second 28.1% 26.5% 27.1% 26.1% 29.2% 28.0% 27.1% 25.7% 26.1% 27.7% 29.3% 
Third 22.4% 24.4% 24.3% 23.6% 22.6% 23.6% 23.8% 25.4% 23.0% 23.4% 22.7% 
Fourth 21.2% 20.7% 21.4% 21.7% 20.0% 19.4% 20.0% 20.0% 19.5% 19.0% 18.4% 
Resource utilization. (Median/IQR) 
Median (IQR) length of 

























Median (IQR) adjusted 





































Charlson Comorbidities, % 
Previous Myocardial 
infarction 
7.9% 7.9% 8.6% 9.1% 9.3% 10.3% 11.0% 11.7% 12.0% 12.4% 12.9% None 
Congestive heart 
failure 
30.3% 30.1% 28.5% 28.7% 28.3% 28.7% 29.1% 30.2% 29.9% 30.5% 31.0% None 
Peripheral vascular 
disease 




1.8% 1.7% 1.7% 2.5% 6.0% 7.2% 7.7% 8.6% 8.8% 8.9% 9.4% None 
Dementia 0.7% 0.8% 0.8% 0.7% 0.7% 0.7% 0.6% 0.7% 0.6% 0.5% 0.5% None 
Chronic pulmonary 
disease 
19.4% 20.5% 20.2% 20.5% 19.4% 20.1% 20.0% 21.0% 21.0% 21.1% 21.4% None 
Rheumatologic disease 1.6% 1.7% 1.7% 1.8% 1.9% 1.9% 2.0% 2.1% 2.3% 2.3% 2.3% None 
Peptic ulcer 1.2% 1.1% 1.0% 1.0% 1.0% 1.1% 1.0% 1.0% 1.0% 0.9% 0.9% None 
Mild liver disease 0.4% 0.4% 0.4% 0.4% 0.3% 0.4% 0.4% 0.5% 0.5% 0.5% 0.6% None 
Diabetes 25.6% 25.5% 26.1% 27.1% 27.4% 28.5% 29.1% 30.2% 31.1% 31.4% 31.8% None 
Diabetes with chronic 
complications 
3.7% 3.7% 3.6% 4.2% 4.2% 4.6% 4.8% 5.6% 5.6% 5.8% 6.1% None 
Hemiplegia or 
paraplegia 
0.4% 0.3% 0.3% 0.4% 0.5% 0.5% 0.5% 0.4% 0.4% 0.4% 0.5% None 




2.4% 2.6% 2.4% 2.7% 2.8% 2.8% 2.7% 2.8% 2.8% 2.9% 3.0% None 
Moderate or severe 
liver disease 
0.1% 0.1% 0.1% 0.2% 0.2% 0.2% 0.2% 0.2% 0.3% 0.2% 0.3% None 
Metastatic solid 
tumour 
0.7% 0.8% 0.8% 0.9% 0.9% 0.9% 0.8% 0.9% 0.8% 0.8% 0.9% None 
AIDS 0.1% 0.1% 0.1% 0.1% 0.1% 0.2% 0.2% 0.2% 0.1% 0.1% 0.1% None 
Other conditions, % 
Smoking 24.7% 27.0% 28.9% 30.3% 31.7% 34.7% 36.0% 37.6% 39.6% 41.1% 43.8% None 
Carotid disease 1.0% 1.1% 1.2% 1.4% 1.6% 1.8% 1.9% 2.1% 2.2% 2.3% 2.3% None 
Atrial Fibrillation 15.9% 16.3% 16.3% 16.2% 15.4% 16.0% 16.2% 17.5% 17.5% 17.7% 18.3% None 
Long-term use of 
anticoagulants 
1.4% 1.7% 1.9% 2.3% 2.4% 3.1% 3.4% 3.9% 3.9% 3.9% 4.4% None 
Previous PCI 6.5% 7.2% 8.4% 9.4% 10.2% 11.6% 12.5% 14.3% 14.8% 15.4% 16.2% None 
Previous CABG 6.7% 6.6% 6.7% 6.6% 7.0% 7.6% 7.7% 8.6% 8.3% 8.3% 8.5% None 
Charlson Comorbidity Index Score, % 
0 (CCI=0) 37.3% 37.0% 37.4% 36.2% 35.0% 34.2% 33.5% 32.1% 31.6% 31.0% 30.2% None 
1 (CCI=1) 33.1% 33.2% 33.6% 33.1% 33.1% 32.1% 32.0% 31.1% 31.4% 31.3% 31.1% None 
2 (CCI=2) 18.7% 18.9% 18.7% 19.0% 19.3% 19.4% 19.7% 19.9% 20.3% 20.5% 20.6% None 
3 (CCI≥3) 10.8% 10.9% 10.4% 11.7% 12.7% 14.2% 14.8% 16.8% 16.8% 17.2% 18.1% None 
Treatments/procedural characteristics, % 
PCI 32.9% 35.4% 38.6% 38.0% 40.0% 41.9% 42.2% 43.2% 45.2% 46.2% 46.7% None 
Coronary Angiography 53.3% 56.4% 58.2% 59.0% 60.3% 63.4% 64.2% 64.3% 67.6% 68.6% 69.3% None 
Infusion of 
thrombolytic agent 
1.7% 1.7% 1.6% 1.3% 1.4% 1.2% 1.0% 1.2% 1.1% 1.1% 1.1% None 
CABG 8.8% 8.4% 9.0% 8.4% 8.2% 8.7% 7.9% 7.8% 8.2% 8.4% 8.4% None 
IABP use 4.1% 4.4% 4.6% 4.6% 5.0% 5.0% 4.7% 4.7% 4.6% 4.4% 4.2% None 
ACS: acute coronary syndrome; IQR: interquartile range; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; CCI: Charlson Comorbidity index; IABP: 
intra-aortic balloon pump. 
 
Table 2: Patient characteristics stratified by categorised Charlson Comorbidity Index Score (CCI).  
 Charlson Comorbidity Index Score (CCI) 
Variables CCI = 0 CCI = 1 CCI = 2 CCI ≥ 3 
Patient demographics 
No. of weighted 










Median (IQR) age, y 62(52, 74) 68(57, 80) 72(61, 82) 72(63, 81) 
Female, % 33.9% 41.8% 44.6% 45.7% 
Race, % 
White 63.5% 62.1% 63.0% 63.7% 
black 6.8% 8.3% 9.1% 10.4% 
Hispanic 5.5% 6.5% 6.6% 7.1% 
Asian/Pacific islander 1.7% 1.8% 1.8% 2.1% 
Native American 0.4% 0.4% 0.5% 0.5% 
other 2.7% 2.7% 2.5% 2.4% 
Missing Race 19.1% 17.9% 16.3% 13.4% 
Primary expected payer, % 
Medicare 41.2% 57.4% 68.9% 74.8% 
Medicaid 5.6% 6.5% 6.9% 6.7% 
Private including HMO 40.7% 26.6% 17.8% 13.8% 
Self-pay 8.3% 6.0% 4.0% 2.4% 
No charge 0.8%7 0.6% 0.4% 0.2% 
Other 3.4% 2.8% 2.2% 1.9% 
Admission/weekend, % 26.0% 25.7% 25.7% 25.7% 
Median zip code income national quartile, % 
Frist 26.2% 30.0% 31.4% 31.1% 
Second 27.0% 27.7% 27.7% 27.2% 
Third 24.4% 23.2% 22.8% 23.2% 
Fourth 22.5% 19.4% 18.1% 18.5% 
Resource utilization. (Median/IQR) 
Median (IQR) length of 
stay (LOS), d 
3(2, 4) 3(2, 6) 4(2, 7) 5(3, 8) 
Median (IQR) adjusted 










Charlson Comorbidity, % 
Previous Myocardial 
infarction 
N/A 9.1% 17.3% 28.0% 
Congestive heart 
failure 
N/A 26.7% 55.8% 72.2% 
Peripheral vascular 
disease 




N/A 3.7% 9.6% 18.9% 
Dementia N/A 0.4% 1.2% 2.2% 
Chronic pulmonary 
disease 
N/A 19.0% 37.8% 49.6% 
Rheumatologic disease N/A 1.9% 3.4% 4.9% 
Peptic ulcer N/A 0.8% 1.8% 2.9% 
Mild liver disease N/A 0.2% 0.6% 1.9% 
Diabetes N/A 37.0% 49.2% 49.3% 
Diabetes with chronic 
complications 
N/A N/A 6.1% 25.0% 
Hemiplegia or 
paraplegia 
N/A N/A 0.5% 2.3% 




N/A N/A 2.9% 15.4% 
Moderate or severe 
liver disease 
N/A N/A N/A 1.3% 
Metastatic solid 
tumour 
N/A N/A N/A 6.0% 
AIDS N/A N/A N/A 1.0% 
Other conditions, % 
Smoking 38.0% 33.0% 30.5% 30.5% 
Carotid disease 0.9% 1.6% 2.3% 3.0% 
Atrial Fibrillation 10.4% 17.2% 21.9% 23.4% 
Long-term use of 
anticoagulants 
1.8% 2.8% 3.8% 4.5% 
Previous PCI 7.3% 12.0% 14.1% 15.6% 
Previous CABG 4.1% 7.3% 10.3% 12.3% 
Treatments/procedural characteristics, % 
PCI 53.5% 40.7% 30.3% 24.0% 
Coronary Angiography 72.0% 62.5% 54.2% 47.0% 
Infusion of 
thrombolytic agent 
1.8% 1.3% 1.0% 0.8% 
CABG 7.2% 9.2% 9.4% 7.8% 
IABP use 3.8% 5.1% 5.2% 4.1% 
ACS: acute coronary syndrome; IQR: interquartile range; PCI: percutaneous coronary intervention; CABG: 




Table 3: Association between categorised Deyo Charlson index scores and recipient of treatments, 
in-hospital clinical outcomes with ACS diagnosis (adjusted odds ratio, 95% confidence intervals † §). 
*Reference is CCI=0; ACS: acute coronary syndrome; PCI: percutaneous coronary intervention; CA: coronary 
angiography; MACCE: major acute cardiovascular and cerebrovascular events: composite of death, cardiac 
complications, stroke, and vascular complications; PCI: percutaneous coronary intervention; CA: coronary 
angiography. 
† Adjustment for age, gender, ethnicity, day of admission (weekday/weekend), median income, type of ACS, If 
the patient smokes, carotid disease, diagnosis of atrial fibrillation, long-term use of anticoagulants, previous 
procedure of percutaneous coronary intervention, previous procedure of coronary artery bypass graft, use of 
intra-aortic balloon pump, infusion of thrombolytic agent and year of hospitalisation. 
§ Adjustment for age, gender, ethnicity, day of admission (weekday/weekend), median income, type of ACS, If 
the patient smokes, carotid disease, diagnosis of atrial fibrillation, long-term use of anticoagulants, previous 
procedure of percutaneous coronary intervention, previous procedure of coronary artery bypass graft, use of 
percutaneous coronary intervention, coronary angiography, coronary artery bypass graft, use of intra-aortic 




 Charlson Comorbidity Index Score (CCI) 
Outcomes* CCI = 1 CCI = 2 CCI ≥ 3 
PCI† 0.74 (0.72, 0.74) 0.55 (0.54, 0.56) 0.47 (0.46, 0.48) 
CA† 0.77 (0.75, 0.78) 0.59 (0.57, 0.60) 0.42 (0.41, 0.43) 
MACCE§ 1.23 (1.20, 1.25) 1.35 (1.32, 1.38) 1.70 (1.66, 1.75) 
Mortality§ 1.31 (1.29, 1.34) 1.45 (1.41, 1.50) 1.74 (1.68, 1.79) 
Acute ischemic 
stroke§ 
1.26 (1.21, 1.31) 1.48 (1.41, 1.55) 2.35 (2.23, 2.46) 
Major Bleeding§ 1.16 (1.13, 1.18) 1.33 (1.29, 1.37) 1.64 (1.59, 1.69) 
Table 4. Secular trends of in-hospital clinical outcomes between 2004 and 2014 in ACS patients. 
 
Variable 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Missing 
Clinical outcomes/ complications, %  
MACCE 8.7% 8.6% 8.2% 8.1% 8.4% 8.0% 7.5% 7.3% 7.2% 7.2% 7.2% None 





0.3% 0.4% 0.5% 0.5% 0.8% 0.8% 0.8% 0.7% 0.8% 0.8% 0.8% None 
Acute ischemic 
stroke 
1.6% 1.6% 1.7% 1.6% 1.8% 1.6% 1.6% 1.5% 1.4% 1.4% 1.6% None 
Vascular 
complications 
0.7% 0.8% 0.8% 0.8% 0.8% 0.8% 0.6% 0.6% 0.5% 0.6% 0.5% None 
Major Bleeding 5.7% 5.3% 5.3% 5.4% 5.4% 5.1% 4.5% 4.2% 4.0% 3.8% 3.6% None 




Table 5: In-hospital clinical outcomes by categorised Charlson Comorbidity Index Score (CCI).  
MACCE: major acute cardiovascular and cerebrovascular events: composite of death, cardiac complications, 





 Charlson Comorbidity Index Score (CCI) 
Outcomes CCI = 0 CCI = 1 CCI = 2 CCI ≥ 3 
MACCE 5.4% 8.0% 9.5% 11.4% 
Mortality 3.3% 5.7% 7.0% 8.1% 
Cardiac complications 0.8% 0.6% 0.5% 0.4% 
Acute ischemic stroke 0.9% 1.4% 1.9% 3.0% 
Vascular complications 0.6% 0.7% 0.7% 0.6% 
Major Bleeding 3.9% 4.7% 5.4% 6.1% 
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